Patient Name: John Doe
MRN: 123456
Test Date: October 12, 2023
Sample Type: Tumor tissue (CT-guided biopsy of lung mass)

Molecular Findings:
    EGFR Mutation: Exon 19 deletion detected (sensitizing mutation).
    T790M Mutation: Not detected.
    ALK Rearrangement: Negative.
    ROS1 Rearrangement: Negative.
    PD-L1 Expression: Low (TPS 5%).

Interpretation:
    Tumor is EGFR mutation-positive (exon 19 deletion), qualifying for first-line osimertinib (Tagrisso).
    No evidence of ALK/ROS1 alterations or high PD-L1 expression.